β‑catenin inhibitors ICG‑001 and pyrvinium sensitize bortezomib‑resistant multiple myeloma cells to bortezomib
Author:
Affiliation:
1. Department of Hematology, Yueyang Second People's Hospital, Yueyang, Hunan 414000, P.R. China
Publisher
Spandidos Publications
Subject
Cancer Research,Oncology
Reference37 articles.
1. Cell of origin and genetic alterations in the pathogenesis of multiple myeloma;Barwick;Front Immunol,2019
2. Multiple myeloma;Kyle;Blood,2008
3. The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of multiple myeloma;Shah;J Immunother Cancer,2020
4. Multiple myeloma: 2018 update on diagnosis, risk-stratification, and management;Rajkumar;Am J Hematol,2018
5. Therapy for relapsed multiple myeloma: Guidelines from the mayo stratification for myeloma and risk-adapted therapy;Dingli;Mayo Clin Proc,2017
Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. BRD4-binding enhancer promotes CRC progression by interacting with YY1 to activate the Wnt pathway through upregulation of TCF7L2;Biochemical Pharmacology;2023-12
2. Pyrvinium Pamoate: Past, Present, and Future as an Anti-Cancer Drug;Biomedicines;2022-12-14
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3